Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Eterna Therapeutics (Nasdaq: ERNA) has announced a stock repurchase program of up to $1 million of its outstanding common stock. The Board of Directors-authorized program allows repurchases through open market transactions, privately negotiated transactions, or other means in compliance with securities laws. The company's management will determine the timing and amount of repurchases based on market conditions, stock price, and other factors. The program has no set expiration date and can be suspended, modified, or discontinued at any time.
Eterna Therapeutics (Nasdaq: ERNA) ha annunciato un programma di riacquisto di azioni per un massimo di 1 milione di dollari delle sue azioni ordinarie in circolazione. Il programma autorizzato dal Consiglio di Amministrazione consente i riacquisti tramite transazioni sul mercato aperto, transazioni negoziate privatamente o altri mezzi conformi alle leggi sui titoli. La direzione dell'azienda determiner脿 il momento e l'importo dei riacquisti in base alle condizioni di mercato, al prezzo delle azioni e ad altri fattori. Il programma non ha una data di scadenza fissa e pu貌 essere sospeso, modificato o interrotto in qualsiasi momento.
Eterna Therapeutics (Nasdaq: ERNA) ha anunciado un programa de recompra de acciones de hasta 1 mill贸n de d贸lares de sus acciones ordinarias en circulaci贸n. El programa autorizado por la Junta Directiva permite recompra a trav茅s de transacciones en el mercado abierto, transacciones negociadas privadamente u otros medios en cumplimiento con las leyes de valores. La direcci贸n de la empresa determinar谩 el momento y la cantidad de las recompras seg煤n las condiciones del mercado, el precio de las acciones y otros factores. El programa no tiene fecha de expiraci贸n establecida y puede ser suspendido, modificado o interrumpido en cualquier momento.
鞚错劙雮� 韰岆澕頁嫳鞀� (Nasdaq: ERNA)電� 斓滊寑 100毵� 雼煬 靸侂嫻鞚� 鞙犿喌 欷戩澑 氤错喌欤茧ゼ 鞛惮毵ろ晿電� 頂勲攴鸽灗鞚� 氚滍憸頄堨姷雼堧嫟. 鞚挫偓須岇棎靹� 鞀轨澑頃� 頂勲攴鸽灗鞚� 瓿店皽 鞁滌灔 瓯半灅, 牍勱车鞁� 瓯半灅 霕愲姅 歃濌秾氩曥潉 欷�靾橅晿電� 旮绊儉 靾橂嫧鞚� 韱淀暣 鞛惮毵るゼ 項堨毄頃╇媹雼�. 須岇偓鞚� 瓴届榿歆勳潃 鞁滌灔 靸來櫓, 欤缄皜 氚� 旮绊儉 鞖旍澑鞐� 霐半澕 鞛惮毵れ潣 鞁滉赴鞕� 鞏戩潉 瓴办爼頃╇媹雼�. 鞚� 頂勲攴鸽灗鞚� 瓿犾爼 毵岆鞚检澊 鞐嗢溂氅� 鞏胳牅霌犾 欷戨嫧, 靾橃爼 霕愲姅 欷戩霅� 靾� 鞛堨姷雼堧嫟.
Eterna Therapeutics (Nasdaq: ERNA) a annonc茅 un programme de rachat d'actions d'un montant pouvant atteindre 1 million de dollars pour ses actions ordinaires en circulation. Le programme autoris茅 par le Conseil d'Administration permet des rachats par le biais de transactions sur le march茅 libre, de transactions n茅goci茅es de mani猫re priv茅e ou par d'autres moyens conformes aux lois sur les valeurs mobili猫res. La direction de l'entreprise d茅terminera le moment et le montant des rachats en fonction des conditions du march茅, du prix des actions et d'autres facteurs. Le programme n'a pas de date d'expiration fixe et peut 锚tre suspendu, modifi茅 ou interrompu 脿 tout moment.
Eterna Therapeutics (Nasdaq: ERNA) hat ein Aktienr眉ckkaufprogramm von bis zu 1 Million Dollar f眉r ihre ausstehenden Stammaktien angek眉ndigt. Das vom Vorstand genehmigte Programm erlaubt R眉ckk盲ufe 眉ber Transaktionen am offenen Markt, privat ausgehandelte Transaktionen oder andere Mittel, die den Wertpapiergesetzen entsprechen. Das Management des Unternehmens wird den Zeitpunkt und die H枚he der R眉ckk盲ufe basierend auf den Marktbedingungen, dem Aktienkurs und anderen Faktoren bestimmen. Das Programm hat kein festes Ablaufdatum und kann jederzeit ausgesetzt, ge盲ndert oder eingestellt werden.
- Board authorization of $1 million stock buyback program indicates confidence in company's value
- Flexible repurchase program with no set expiration date allows strategic timing of purchases
- Program demonstrates commitment to enhancing shareholder value
- Relatively small buyback amount of $1 million may have impact on share price
- Program implementation depends on market conditions and may not be fully executed
Insights
CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (Nasdaq: ERNA), a leader in cell therapies, today announced that its Board of Directors has authorized a stock repurchase program of up to
Under the stock repurchase program, the repurchases may be made by the Company from time to time through open market transactions, privately negotiated transactions, or other means in accordance with applicable securities laws. The timing and amount of repurchases will be determined by the company鈥檚 management, taking into consideration market conditions, stock price, and other factors. The program does not have a set expiration date and may be suspended, modified or discontinued at any time without prior notice.
鈥淭his buyback program underscores our belief in Eterna Therapeutics鈥� trajectory,鈥� says Sanjeev Luther, President and CEO. For more information, please visit .
About Eterna Therapeutics Inc.
Eterna Therapeutics is a publicly traded, preclinical-stage company focused on using cutting-edge tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors, with an initial emphasis on triple-negative breast cancer (TNBC) and platinum-resistant, TP53-mutant ovarian cancer. The company is currently focused on advancing its lead product ERNA-101, an induced allogenic mesenchymal stem cell (鈥渋MSC鈥�) product, designed to selectively deliver the pro-inflammatory cytokines IL-7 and IL-15 to the tumor microenvironment (TME) in order to drive significant anti-tumor immunity. ERNA-101 is built on the company's in-licensed core technology, which utilizes a best-in-class approach to engineer allogenic iPSCs to express genes of interest and to efficiently differentiate these cells into iMSCs. For more information, please visit .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to if and when the Company will repurchase the stock authorized by its Board and the impact of the buyback program to the Company and its shareholders. Forward-looking statements are based upon Eterna's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Eterna's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Investor Relations Contact:
investors@eternatx.com
FAQ
How much is Eterna Therapeutics (ERNA) stock buyback program worth?
When does Eterna Therapeutics (ERNA) stock buyback program expire?
How will Eterna Therapeutics (ERNA) implement its stock buyback program?
